1. Home
  2. SWX vs ERAS Comparison

SWX vs ERAS Comparison

Compare SWX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southwest Gas Holdings Inc. (DE)

SWX

Southwest Gas Holdings Inc. (DE)

HOLD

Current Price

$90.27

Market Cap

6.3B

Sector

Utilities

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$19.11

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWX
ERAS
Founded
1931
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.5B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
SWX
ERAS
Price
$90.27
$19.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
12
Target Price
$87.40
$14.25
AVG Volume (30 Days)
379.9K
6.0M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
2.74%
N/A
EPS Growth
120.29
36.23
EPS
6.08
N/A
Revenue
$5,433,972,000.00
N/A
Revenue This Year
$18.48
N/A
Revenue Next Year
$2.61
N/A
P/E Ratio
$14.80
N/A
Revenue Growth
9.56
N/A
52 Week Low
$66.93
$1.06
52 Week High
$93.44
$24.28

Technical Indicators

Market Signals
Indicator
SWX
ERAS
Relative Strength Index (RSI) 55.28 54.91
Support Level $76.66 $1.98
Resistance Level $93.44 N/A
Average True Range (ATR) 1.63 1.98
MACD -0.19 0.13
Stochastic Oscillator 45.80 49.95

Price Performance

Historical Comparison
SWX
ERAS

About SWX Southwest Gas Holdings Inc. (DE)

Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution segment. The Natural gas distribution segment encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. Its division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: